Swiss National Bank Has $2.65 Million Stock Holdings in Travere Therapeutics, Inc. (NASDAQ:TVTX)

Swiss National Bank lifted its stake in Travere Therapeutics, Inc. (NASDAQ:TVTX) by 12.8% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 151,900 shares of the company’s stock after purchasing an additional 17,200 shares during the quarter. Swiss National Bank owned 0.19% of Travere Therapeutics worth $2,646,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of the stock. E Fund Management Co. Ltd. acquired a new position in Travere Therapeutics in the 4th quarter worth approximately $217,000. Arizona State Retirement System grew its holdings in shares of Travere Therapeutics by 13.5% during the fourth quarter. Arizona State Retirement System now owns 22,396 shares of the company’s stock valued at $390,000 after buying an additional 2,666 shares in the last quarter. Aigen Investment Management LP lifted its stake in Travere Therapeutics by 56.6% in the 4th quarter. Aigen Investment Management LP now owns 19,072 shares of the company’s stock worth $332,000 after acquiring an additional 6,892 shares in the last quarter. Victory Capital Management Inc. purchased a new stake in Travere Therapeutics in the 4th quarter worth about $182,000. Finally, Charles Schwab Investment Management Inc. grew its stake in Travere Therapeutics by 16.6% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 661,603 shares of the company’s stock valued at $11,525,000 after acquiring an additional 94,194 shares in the last quarter.

Analyst Upgrades and Downgrades

TVTX has been the topic of a number of research analyst reports. HC Wainwright boosted their price objective on shares of Travere Therapeutics from $18.00 to $22.00 and gave the company a “buy” rating in a research report on Wednesday, January 15th. Scotiabank lifted their price objective on Travere Therapeutics from $27.00 to $32.00 and gave the company a “sector outperform” rating in a research report on Wednesday, February 12th. JPMorgan Chase & Co. boosted their price target on Travere Therapeutics from $42.00 to $44.00 and gave the company an “overweight” rating in a research note on Wednesday, February 26th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Travere Therapeutics in a research report on Friday, February 21st. Finally, Citigroup increased their price target on shares of Travere Therapeutics from $31.00 to $35.00 and gave the stock a “buy” rating in a research note on Monday, February 24th. One equities research analyst has rated the stock with a hold rating and thirteen have given a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $30.62.

Insider Activity at Travere Therapeutics

In related news, insider Peter Heerma sold 1,584 shares of the firm’s stock in a transaction on Wednesday, January 22nd. The stock was sold at an average price of $18.94, for a total value of $30,000.96. Following the completion of the transaction, the insider now directly owns 106,374 shares of the company’s stock, valued at $2,014,723.56. This trade represents a 1.47 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CAO Sandra Calvin sold 54,244 shares of the business’s stock in a transaction on Tuesday, February 11th. The shares were sold at an average price of $25.00, for a total transaction of $1,356,100.00. Following the completion of the sale, the chief accounting officer now directly owns 54,410 shares in the company, valued at $1,360,250. This trade represents a 49.92 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 191,335 shares of company stock worth $4,194,712 in the last ninety days. 3.75% of the stock is currently owned by insiders.

Travere Therapeutics Stock Down 2.0 %

TVTX stock opened at $20.37 on Friday. The company has a debt-to-equity ratio of 24.96, a current ratio of 1.71 and a quick ratio of 1.68. The company has a 50-day moving average of $20.73 and a two-hundred day moving average of $18.40. The stock has a market capitalization of $1.81 billion, a price-to-earnings ratio of -4.97 and a beta of 0.75. Travere Therapeutics, Inc. has a 52-week low of $5.12 and a 52-week high of $25.29.

Travere Therapeutics (NASDAQ:TVTX) last issued its quarterly earnings results on Thursday, February 20th. The company reported ($0.73) EPS for the quarter, missing the consensus estimate of ($0.58) by ($0.15). Travere Therapeutics had a negative return on equity of 1,636.87% and a negative net margin of 137.90%. The business had revenue of $74.79 million during the quarter, compared to the consensus estimate of $72.38 million. As a group, equities research analysts anticipate that Travere Therapeutics, Inc. will post -1.4 EPS for the current year.

About Travere Therapeutics

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.